invest1 publisher
GH Research Gets Buy Rating on GH001 Momentum, FDA Hold Resolution and Competitive Edge
A Seeking Alpha analyst initiated coverage on GH Research at Buy after the company resolved the FDA clinical hold on GH001, and the note rests its competitive case on dosing time and fewer clinic visits than SPRAVATO.
Publishers:seekingalpha.com
Reality
- Evidence18
- Adoption
- Insufficient
- Hype gap+38
- Incentives62
- Confidence46